Atal Bihari Vajpayee Medical University, Uttar Pradesh, has started the first round of counselling for CPET 2025 admissions.

This is a pivotal step in scaling our mission, not just to build powerful technology, but to create solutions that enable manufacturers to operate more transparently, ethically and sustainably.

Pune has become a major player in India's expanding manufacturing sector and the country's leader in industrial real estate ...

Kinetic Communications inaugurated a fully-automated controller manufacturing line in Pune, increasing its manufacturing ...

The Union Cabinet on Wednesday approved the second phase of the Pune Metro project. Under this phase, two new elevated ...

Key Takeaways ART-101, a novel PSMA-targeting small molecule, received FDA IND clearance for mCRPC treatment, enabling a phase 1 trial launch. Preclinical studies show ART-101 has higher tumor uptake ...

Is ChatGPT the secret behind Infosys founder’s 5x productivity boost? Here’s how Narayana Murthy cut his lecture prep time from 30 hours to just 5 using AI Last updated: June 18, 2025 | 21:35 ...

Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a ...

The Maharashtra Cabinet on Tuesday gave approval to develop the first phase of the ambitious Virar-Alibaug Multi-Modal Transport Corridor, a 165-km arterial route designed to reduce congestion in ...

Overall, 88 healthy adults without HIV-1 (median age, 30 years; 65% men) were randomly assigned to receive either the vaccine (n = 72) or placebo (n = 16) from July 2021 to November 2022 and were ...

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs ...

In the recommended phase 2 dose safety population (n = 45; 3.5 mg [Day 1], 18 mg [Day 8], 300 mg Q3W or Q6W IV), the most common treatment related adverse events were infusion-related reactions (22.2% ...